Antagonism of LPS and IFN-γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 6, 1998, Pages 813-820

  Stefano, George B ^a,b   Salzet, Michel ^c   Magazine, Harold I ^d   Bilfinger, Thomas V ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIV LILLE   (France)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Adenylate cyclase; Anandamide; Endothelium; Morphine; Nitric oxide; Nitric oxide synthase; Saphenous vein

Indexed keywords

ACETYLCHOLINE; ADENYLATE CYCLASE; ANANDAMIDE; CYCLIC AMP; DRUG VEHICLE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MORPHINE; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE ANTAGONIST; RIMONABANT;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ADENYLATE CYCLASE; ARACHIDONIC ACIDS; ENDOTHELIUM, VASCULAR; HUMANS; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MORPHINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYUNSATURATED ALKAMIDES; SAPHENOUS VEIN;

EID: 0031749558     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199806000-00003     Document Type: Article

References (37)

1. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 1995;3:2-32.
2. Lefer DJ, Nakanishi K, Vinten-Johansen J. Endothelial and myocardial cell protection by a cysteine-containing nitric oxide donor after myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 1992;22:S34-43.
3. Stefano GB, Scharrer B, Smith EM, et al. Opioid and opiate immunoregulatory processes. Crit Rev Immunol 1996;16:109-44.
4. Bilfinger TV, Hartman A, Liu Y, Magazine HI, Stefano GB. Cryopreserved veins used for myocardial revascularization: a 5 year experience and a possible mechanism for their increased failure. Ann Thorac Surg 1996;63:1063-9.
5. Pacifici R, Minetti M, Zuccarro P, Pietraforte D. Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release. Int J Immunopharmacol 1995;17:771-7.
6. Iuvone T, Capasso A, D'Acquisto F, Carnuccio R. Opioid inhibits the induction of nitric oxide synthase in J774 macrophages. Biochem Biophys, Res Commun 1995;212:975-80.
7. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-KB/Rel activation. Mol Pharmacol 1996;50:334-41.
8. 3 opiate receptor in endothelial cells: coupling to nitric oxide production and vasodilation. J Biol Chem 1995;270:30290-3.
9. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 1996;271: 19238-42.
10. Stefano GB, Salzet B, Salzet M. Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release. Brain Res 1997;753:219-24.
11. Liu Y, Shenouda D, Bilfinger TV, Stefano ML, Magazine HI, Stefano GB. Morphine stimulates nitric oxide release from invertebrate microglia. Brain Res 1996;722:125-31.
12. Magazine HI, Liu Y, Bilfinger TV, Fricchione GL, Stefano GB. Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J Immunol 1996;48:45-50.
13. Stefano GB, Catapane EJ, Kream RM. Characterization of the dopamine stimulated adenylate cyclase in the pedal ganglia of Mytilus edulis: interactions with etorphine, B-endorphin, DALA and methionine enkephalin. Cell Mol Neurobiol 1981;1:57-68.
14. Stefano GB. Comparative aspects of opioid-dopamine interaction. Cell Mol Neurobiol 1982;2:167-78.
15. Howlett AC. Cannabinoid inhibition of adenylate cyclase: biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985;27:429-36.
16. Devane MA, Spain JW, Coscia CJ, Howlett AC. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J Neurochem 1986;46:1929-35.
17. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 1992;42:736-42.
18. Osugi T, Taniura H, Ikemoto M, Miki N. Effects of chronic exposure of NG108-15 cells to morphine or ethanol on binding of nuclear factors to cAMP-response element. Biochem Biophys Res Commun 1991;174:25-31.
19. Carpenter GW, Garza HH Jr, Gebhardt BM, Carr DJ. Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain Behav Immun 1994;8: 185-203.
20. 9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism tor cannabinoid-mediated immunosuppression. Life Sci 1992;51:25-30.
21. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
22. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993;214:173-80.
23. Lynn AB, Herkenham M. Legalization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-23.
24. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper D, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995;92:3376-80.
25. Bodnar A, Pasternak GW. Aging and analgesic mechanisms. In: Makman MH, Stefano GB, eds. Neuroregulatory mechanisms in aging. Oxford: Pergamon Press, 1993:137-58.
26. Makman MH, Bilfinger TV, Stefano GB. Human granulocytes contain an opiate receptor mediating inhibition of cytokine-induced activation and chemotaxis. J Immunol 1995;154:1323-30.
27. Stefano GB, Hall B, Makman MH, Dvorkin B. Opioids inhibit potassium-stimulated dopamine release in the marine mussel Mytilus edulis and in the cephalopod. Octopus bimaculatus. Science 1981;213:928-30.
28. Magazine HI. Detection of endothelial cell-derived nitric oxide: current trends and future directions. Adv Neuroimmunol 1995;5:479-85.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-73.
30. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990;87:10043-7.
31. Kaminski NE, Koh WS, Lee M, Yang KH, Kessler FK. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 1994;48: 1899-908.
32. Childers SR, Fleming L, Konkoy C, et al. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann N Y Acad Sci 1992;654:33-51.
33. 3-opiate receptors. Eur J Pharmacol 1995;273:R5-6.
34. O'Brien CP. Drug addiction and drug abuse. In: Hardman JG, Limbird LE, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:557-79.
35. Stefano GB, Scharrer B. Endogenous morphine and related opiates, a new class of chemical messengers. Adv Neuroimmunol 1994;4:57-68.
36. DeCaterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-81.
37. Engelman DT, Wakanabe M, Engelman RM. Constitutive nitric oxide release is impaired after ischemia and reperfusion. J Thorac Cardiovasc Surg 1995;110:1047-53.